治疗心力衰竭的内扩散剂治疗. 早,晚,还是根本没有?
1Sticares Cardiovascular Research Foundation, Rotterdam, The Netherlands.
Circulation
|May 1, 1993
概括
内扩张剂治疗,结合内和血管扩张作用,显示出对心力衰竭的承诺. 然而,增加循环AMP (cAMP) 的药物可能会增加死亡率,而敏感剂则为轻度至中度心力衰竭提供了更安全的替代方案.
科学领域:
- 药理学和心血管医学.
- 药物发现和开发 药物发现和开发
- 心脏衰竭病理生理学 病理生理学
背景情况:
- 结合积极的内和血管扩张效应的内扩散剂疗法在概念上是心力衰竭的理想治疗方法.
- 现有的口服活性内扩增剂,包括β-激动剂,多巴胺基化合物和固酶 (PDE) 抑制剂,尚未得到广泛接受.
- 有关主要通过PDE抑制作用的药物的安全性和有效性存在担忧,可能会增加晚期心力衰竭中的死亡率和心律失常性.
研究的目的:
- 评估心力衰竭中不同内扩展剂策略的治疗潜力.
- 评估与PDE抑制和敏感化相关的风险和益处.
- 探索改善心脏收缩率和控制心力衰竭的替代方法.
主要方法:
- 审查和分析有关各种内扩散剂药物类别的现有数据.
- 作用机制的比较,包括循环AMP (cAMP) 升高与敏感化.
- 评估不同心力衰竭严重程度组的临床疗效和不良事件概况.
主要成果:
- 主要的PDE抑制导致cAMP增加可能是无效的,并增加晚期心力衰竭的死亡率.
- 结合的β-agonists和多巴胺化合物已经显示出有限的长期临床疗效和潜在的心律失常.
- 具有敏感性特性的部分PDE抑制剂,如pimobendan,在轻度至中度心力衰竭中可能更有效和更安全.
结论:
- 增加cAMP的内扩张策略可能不适合晚期心力衰竭.
- 将敏感化与有限的PDE抑制相结合的药物在轻度至中度心力衰竭中看起来很有希望.
- 需要进一步的研究来澄清这些药物的长期效果,安全性和最佳使用,包括神经幽默调节和心率降低的潜在益处.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.